City voices fury at collapse of Glaxo merger

More than pounds 13bn wiped off combined value of pharmaceuticals giant and SmithKline Beecham as world's largest corporate deal disintegrates

Glaxo Wellcome and SmithKline Beecham felt the full force of the City's anger yesterday as the collapse of their merger talks wiped more than pounds 13bn off their combined value and details emerged of the personality and culture clashes that brought the deal crashing down.

The collapse of the deal, which would have created the world's biggest drugs group and the third biggest global company, saw Glaxo Wellcome's shares slump by almost 13 per cent to 1657p, while SmithKline Beecham's stock fell more than 10 per cent to 724p.

The failure of the two companies to complete the merger after clashing over the question of who would run the company stunned the City but also drew widespread criticism from institutional shareholders and analysts.

Large investors warned that both companies now had a major task on their hands to rebuild shareholder confidence, particularly SmithKline, which had already called off a merger with American Home Products, the US drugs group, last month to broker a deal with Glaxo.

"It is very unfortunate that in the middle of a deal you have to change tack. It suggests that the two sides had not fully understood and communicated with each other before rushing headlong into a deal which is not the best course of action," said one large shareholder in the two drugs groups.

Another fund manager said: "This damages the credibility of both groups. SmithKline have already jilted the bride to run off with the best man. Now they are cannot even get it together with the best man. We want to know more about the real reasons for the collapse in the talks."

The collapse of the deal became inevitable after the two sides clashed at a meeting in New York last Friday over the respective roles of its five-man executive board and the apportionment of senior management jobs between Glaxo and SmithKline personnel.

Under the deal Sir Richard Sykes, the Glaxo chairman, would have become executive chairman of the merged group and Jan Leschly, chief executive of SmithKline, its new chief executive. The other executive members would have been Glaxo's chief executive, Bob Ingram, and its finance director John Coombe and SmithKline's chief operating officer, Jean Pierre Garnier.

Mr Leschly would also have been chairman of a larger executive committee. But it emerged that its powers would have been limited with Sir Richard wanting to remain in charge of all major strategic decisions. Likewise, the two sides were unable to agree on whether Mr Garnier or Mr Ingram would be chief operating officer or the division of roles in the next tier of management.

Glaxo executives also questioned why there should be a 50:50 split of management jobs when SmithKline's pharmaceutical sales were only 55 per cent of Glaxo's. There also appears to have been a growing realisation on the part of Glaxo that the cultures of the two groups were incompatible. Glaxo operates as a decentralised organisation with authority and responsibility devolved to regional and divisional heads while SmithKline is driven very much from the centre.

Nevertheless, institutional shareholders were aghast that these differences had not been ironed out before the two sides disclosed their merger talks three weeks ago, stating that respective valuations and the division of top jobs had already been agreed.

"I am very perturbed that companies of this stature with experienced management teams could not put a deal together. If it is about jobs for the boys then I would have expected more from both groups," said one.

Tim Franklin, pharmaceutical analyst at Greig Middleton said: "This is a major disappointment. Both companies are under pressure to do something to maintain investor confidence."

Analysts also speculated that Glaxo may have wanted to force the disposal of SmithKline's healthcare division, which it considered to be far less important than its pharmaceutical arm, while there were also question marks over DPS, SmithKline's troubled US pharmacy benefit manager.

"You never know what nasties they discovered when they started to look at each other closely," said an institutional shareholder.

SmithKline and Glaxo now intend to launch separate charm offensives on the City over the next few days and weeks to calm investor fears and try and salvage their reputations.

The collapse of the deal robs several senior executives of huge payouts and the City of at least pounds 100m in fees. Mr Leschly alone stood to make a paper profit of more than pounds 17m from UK and US share options.

However, it will save thousands of jobs among the 21,000 UK workforce of the two companies. Roger Lyons, general secretary of MSF, the white collar science union, said: "This is great news. The company ignored the interests of its employees and anybody else. Now it seems that five executives have fallen out over the division of the spoils and perhaps the group's strategy."

The rationale for the merger was to create a research and development powerhouse with annual expenditure of more than pounds 2bn a year. SmithKline has poured money into genomics, a process designed to identify hundreds of compounds that could be used to develop drugs. This technology was supposed to have fitted neatly with Glaxo's advanced screening techniques, which analysts believe could have lead to the development of a vast array of new drugs.

One analyst said: "I would rather the two groups walk away than proceed with a turkey. When you add a poor drugs pipeline with another poor pipeline then you get an even bigger poor drugs pipeline."

Outlook, page 21

Wrong chemistry

20 Jan: SmithKline Beecham announces it is in merger talks with American Home Products

24 Jan: Glaxo chairman Sir Richard Sykes telephones Jan Leschly, chief executive of SmithKline, and asks whether it would be interested in a merger with Glaxo instead

27 Jan: Sykes flies to New York and meets Leschly in the Rockefeller Center, headquarters of SmithKline's advisers Lazard Freres, to thrash out a deal

30 Jan: SmithKline breaks off negotiations with AHP and announces it is in merger talks with Glaxo. Respective valuations and top management of combined group agreed in advance

17 Feb: SmithKline reports 7 per cent rise in pre-tax profits for 1997 and says it expects to announce the Glaxo merger in early March

19 Feb: Glaxo reports 9 per cent drop in 1997 profits but makes no comment on the progress of the merger talks

20 Feb: Sykes meets Leschly in New York and says Glaxo is not prepared to proceed on the previously agreed terms

22 Feb: SmithKline chairman Sir Peter Walters and Glaxo deputy chairman Sir Roger Hurn meet in London in attempt to rescue the merger

23 Feb: SmithKline terminates merger talks, citing `insurmountable differences' with Glaxo over management philosophy and corporate culture

24 Feb: Glaxo and SmithKline shares plunge 13 per cent and 10 per cent respectively as recriminations begin and the City vents its anger

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
Arts and Entertainment
Kara Tointon and Jeremy Piven star in Mr Selfridge
tvActress Kara Tointon on what to expect from Series 3
Voices
Winston Churchill, then prime minister, outside No 10 in June 1943
voicesA C Benson called him 'a horrid little fellow', George Orwell would have shot him, but what a giant he seems now, says DJ Taylor
News
i100
Sport
footballBrighton vs Arsenal match report
Arts and Entertainment
Benedict Cumberbatch has spoken about the lack of opportunities for black British actors in the UK
film
News
ebooks
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Tax Assistant

Negotiable: Recruitment Genius: A Tax Assistant is required to join a leading ...

Recruitment Genius: Outbound Sales Executive - OTE £25,000

£16000 - £25000 per annum: Recruitment Genius: This is an exciting opportunity...

Ashdown Group: Java Developer / J2EE Developer - Watford - £45,000 - £47,000

£45000 - £47000 per annum + bonus + benefits: Ashdown Group: Java Developer / ...

Ashdown Group: Marketing Product Manager - (Financial Services) - SW London

£35000 - £38000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...

Day In a Page

Iraq invasion 2003: The bloody warnings six wise men gave to Tony Blair as he prepared to launch poorly planned campaign

What the six wise men told Tony Blair

Months before the invasion of Iraq in 2003, experts sought to warn the PM about his plans. Here, four of them recall that day
25 years of The Independent on Sunday: The stories, the writers and the changes over the last quarter of a century

25 years of The Independent on Sunday

The stories, the writers and the changes over the last quarter of a century
Homeless Veterans appeal: 'Really caring is a dangerous emotion in this kind of work'

Homeless Veterans appeal

As head of The Soldiers' Charity, Martin Rutledge has to temper compassion with realism. He tells Chris Green how his Army career prepared him
Wu-Tang Clan and The Sexual Objects offer fans a chance to own the only copies of their latest albums

Smash hit go under the hammer

It's nice to pick up a new record once in a while, but the purchasers of two latest releases can go a step further - by buying the only copy
Geeks who rocked the world: Documentary looks back at origins of the computer-games industry

The geeks who rocked the world

A new documentary looks back at origins of the computer-games industry
Belle & Sebastian interview: Stuart Murdoch reveals how the band is taking a new direction

Belle & Sebastian is taking a new direction

Twenty years ago, Belle & Sebastian was a fey indie band from Glasgow. It still is – except today, as prime mover Stuart Murdoch admits, it has a global cult following, from Hollywood to South Korea
America: Land of the free, home of the political dynasty

America: Land of the free, home of the political dynasty

These days in the US things are pretty much stuck where they are, both in politics and society at large, says Rupert Cornwell
A graphic history of US civil rights – in comic book form

A graphic history of US civil rights – in comic book form

A veteran of the Fifties campaigns is inspiring a new generation of activists
Winston Churchill: the enigma of a British hero

Winston Churchill: the enigma of a British hero

A C Benson called him 'a horrid little fellow', George Orwell would have shot him, but what a giant he seems now, says DJ Taylor
Growing mussels: Precious freshwater shellfish are thriving in a unique green project

Growing mussels

Precious freshwater shellfish are thriving in a unique green project
Diana Krall: The jazz singer on being friends with Elton John, outer space and skiing in Dubai

Diana Krall interview

The jazz singer on being friends with Elton John, outer space and skiing in Dubai
Pinstriped for action: A glimpse of what the very rich man will be wearing this winter

Pinstriped for action

A glimpse of what the very rich man will be wearing this winter
Russell T Davies & Ben Cook: 'Our friendship flourished online. You can share some very revelatory moments at four in the morning…'

Russell T Davies & Ben Cook: How we met

'Our friendship flourished online. You can share some very revelatory moments at four in the morning…'
Bill Granger recipes: Our chef serves up his favourite Japanese dishes

Bill Granger's Japanese recipes

Stock up on mirin, soy and miso and you have the makings of everyday Japanese cuisine
Michael Calvin: How we need more Eric Cantonas to knock some sense into us

Michael Calvin's Last Word

How we need more Eric Cantonas to knock some sense into us